It was June 2014 when the electrifying news came out of Yale University that a dermatologist named Brett King saw successful results after treating an alopecia areata patient with a Janus kinase (JAK) inhibitor drug. On the 10th anniversary of this milestone, the National Alopecia Areata Foundation is very proud to have Dr. King address the General Session of its upcoming 39th Patient Conference in Washington, DC, June 27-30. Register now so you can hear Dr. King’s remarks on the current state of alopecia areata research and the outlook on upcoming new treatments. Dr. King specializes in the treatment of inflammatory and autoimmune skin diseases. He pioneered the use of JAK inhibitors in dermatology, and his work revealed the utility of this class of medicines for the treatment of alopecia areata in addition to other autoimmune diseases. In 2022, Dr. King was named a Patient Care Hero by the American Academy of Dermatology for his work. He has been the lead investigator on multiple clinical trials for JAK inhibitors in alopecia areata to test their effectiveness. Additionally, Dr. King sits on NAAF’s Research Advisory Council and, since 2023, NAAF’s Board of Directors.
